Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor used in combination with other antiretroviral medicines. Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg). Reverse transcriptase is the enzyme with which HIV generates complementary DNA (cDNA) to its RNA genome - this cDNA is then inserted into the host cell genome, where it can be transcribed into viral RNA for the purposes of replication. Doravirine is taken orally and transported into the cell via a drug transporter. Doravirine then inhibits reverse transcriptase which inhibits HIV-1 replication. Less viral proteins are therefore produced, and there is a reduction in new viruses being formed.

Doravirine Pathway References